Buspirone Shows Promising Benefits for Central Sleep Apnea, Though Not Yet Guideline-Recommended
Buspirone reduces CO2 chemosensitivity and significantly decreases central apnea events in patients with heart failure-related CSA, though it is not currently included in the 2025 AASM treatment guidelines.
Current Guideline Status
The most recent 2025 American Academy of Sleep Medicine Clinical Practice Guideline for CSA treatment does not include buspirone among its recommended therapies 1. The guideline focuses on:
- Continuous positive airway pressure (CPAP)
- Bilevel PAP with backup rate
- Adaptive servo-ventilation
- Transvenous phrenic nerve stimulation
This absence from guidelines reflects the limited evidence base, despite promising research findings.
Evidence for Buspirone's Benefits
Mechanism of Action
Buspirone is a 5-HT1A receptor agonist that inhibits serotonergic chemoreceptor neuron firing, which directly addresses a core pathophysiological mechanism in CSA 2.
Clinical Trial Results in Heart Failure-Related CSA
The BREATH study (2021) provides the strongest evidence for buspirone's efficacy 2:
Primary outcomes:
- 50% of patients achieved clinically significant CO2 chemosensitivity reduction (>0.5 L/min/mmHg) versus only 6.7% with placebo (P = 0.016)
- 41% reduction in CO2 chemosensitivity from baseline (P = 0.001)
Sleep apnea improvements:
- 42% reduction in apnea-hypopnea index (AHI)
- 79% reduction in central apnea index at nighttime
- 77% reduction in oxygen desaturation index at nighttime
- 78% reduction in central apnea index during daytime
- All improvements were statistically significant (P < 0.01)
Safety profile:
- No serious adverse events reported
- Well-tolerated at 15 mg three times daily for one week
Evidence in Spinal Cord Injury Patients
A 2020 study demonstrated buspirone's efficacy in chronic SCI patients with sleep-disordered breathing 3:
- Significantly widened CO2 reserve (-3.6 ± 0.9 mmHg vs. -1.8 ± 1.5 mmHg placebo, P < 0.001)
- Decreased controller gain (1.8 ± 0.4 vs. 4.0 ± 2.0 L/(mmHg·min), P = 0.025)
- Reduced susceptibility to induced hypocapnic central apnea
Critical Limitations
Why Buspirone Isn't Guideline-Recommended
A 2023 Cochrane systematic review identified major evidence gaps 4:
- Very low certainty evidence for all pharmacological CSA treatments
- Short-term follow-up only (3 days to 1 week in most studies)
- Small sample sizes (studies included 5-18 participants)
- Lack of patient-centered outcomes: No data on quality of life, sleep quality, or long-term cardiovascular outcomes
- No mortality data for buspirone specifically
The FDA label confirms buspirone is approved only for generalized anxiety disorder, not CSA 5.
Clinical Considerations
When to Consider Buspirone
Despite lack of guideline support, buspirone may be considered in specific scenarios:
- Heart failure patients with CSA who have failed or cannot tolerate PAP therapy
- Patients with contraindications to phrenic nerve stimulation
- As adjunctive therapy when residual central events persist despite optimized treatment
Dosing from Available Evidence
- Start: 7.5 mg twice daily
- Target: 15 mg three times daily (45 mg/day total)
- Duration studied: 1 week (optimal duration unknown)
Important Caveats
Drug interactions 5:
- Avoid MAOIs (2-week washout required)
- CYP3A4 interactions (avoid strong inhibitors like ketoconazole, grapefruit juice)
- May prolong prothrombin time with warfarin
Contraindications 5:
- Severe hepatic or renal impairment (buspirone levels increase significantly)
Monitoring requirements 5:
- Discontinue 48 hours before urine catecholamine testing (causes false-positive metanephrine)
- Assess for restlessness/akathisia early in treatment
The Evidence Gap
The 2025 AASM guideline emphasizes that optimal CSA management must prioritize patient-reported outcomes and underlying condition treatment, not just eliminating respiratory events 1. Buspirone studies have focused exclusively on polysomnographic parameters without demonstrating improvements in:
- Quality of life
- Cardiovascular mortality
- Heart failure hospitalizations
- Long-term safety beyond 1 week
Until randomized controlled trials demonstrate benefits in these clinically meaningful outcomes with adequate follow-up duration, buspirone remains an off-label option supported by mechanistic rationale and short-term physiological improvements but lacking the evidence base required for guideline inclusion.